miR-181a - regulatory roles, cancer-associated signaling pathway disruptions, and therapeutic potential

Sep 21, 2026

Uploaded by Ophelia

microRNA-181a (miR-181a) functions as a key post-transcriptional regulator of many mRNA transcripts and noncoding RNAs, shaping proliferation, cancer stemness, apoptosis, and immune responses. Abnormal miR-181a expression is documented across multiple cancers, supporting its value as a genomic vulnerability and biomarker. The article reviews links between miR-181a and poor patient outcomes, details mechanisms of miR-181a activity and processing, and maps its roles across regulatory cancer signaling pathways, cellular processes, and the tumor microenvironment.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages64

Reading Time2 h 41 min

AccessFree to download

Abstract

Introduction

microRNA-181a as a regulatory microRNA

miRNA biogenesis and processing overview

Areas covered

Patient outcome correlations

Mechanisms of miR-181a activity and processing

Regulatory cancer signaling pathways

Tumor microenvironment involvement

Expert opinion

Therapeutic targeting and biomarker relevance

Future research directions

Author Manuscript Author Manuscript Author Manuscript Author Manuscript | | HHS Public Access
Author manuscript
Expert Opin Ther Targets. Author manuscript; available in PMC 2025 May 06. | | --- | --- | Published in final edited form as: Expert Opin Ther Targets. 2024 December ; 28(12): 1061–1091. doi:10.1080/14728222.2024.2433687 . miR-181a: regulatory roles, cancer-associated signaling pathway disruptions, and therapeutic potential Grace McIntyrea,b, Zoe Jacksonc, Jose Colinaa,b, Sreeja Sekhara,b, Analisa DiFeoa,ba Department of Pathology, Rackham Graduate School, University of Michigan, Ann Arbor, MI, USA bRogel Cancer Center, University of Michigan, Ann Arbor, MI, USA c Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA Abstract Introduction: microRNA-181a ( miR-181a) is a crucial post-transcriptional regulator of many mRNA transcripts and noncoding-RNAs, influencing cell proliferation, cancer cell stemness, apoptosis, and immune responses. Its abnormal expression is well-characterized in numerous cancers, establishing it as a significant genomic vulnerability and biomarker in cancer research. Areas covered: Here, we summarize miR-181a’s correlation with poor patient outcomes across numerous cancers and the mechanisms governing miR-181a’s activity and processing. We comprehensively describe miR-181a’s involvement in multiple regulatory cancer signaling pathways, cellular processes, and the tumor microenvironment. We also discuss current therapeutic approaches to targeting miR-181a, highlighting their limitations and future potential. Expert opinion: miR-181ais a clinically relevant pan-cancer biomarker with potential as a therapeutic target. Its regulatory control of tumorigenic signaling pathways and immune responses positions it as a promising candidate for personalized treatments. The success of miR-181a as a target relies on the development of specific therapeutics platforms. Future research on miR-181a’s role in the tumor microenvironment and the RNA binding proteins that regulate its stability will help uncover new techniques to targeting miR-181a. Further research into miR-181a serum levels in patients undergoing therapy will help to better stratify patients and enhance therapeutic success. Keywords Biomarker; cancer; miR-181a ; microRNA ; microRNA therapeutics; microRNA processing; microRNA regulation; signaling pathways This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. CONTACT Analisa DiFeo adifeo@umich.edu Department of Pathology, Rackham Graduate School, University of Michigan, 1150 W Medical Center Dr. Ste 752, Ann Arbor, MI 48109, USA. Declaration of interest The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. Author Manuscript Author Manuscript Author Manuscript Author Manuscript McIntyre et al. Page 2 1. Introduction Cancer arises when normal cellular processes become disrupted. Tumor suppressive redundancies, feedback loops, extrinsic immune surveillance, programmed cell death, and other mechanisms exist to guard against transformation. When these mechanisms fail, neoplasia and carcinogenesis result as competitive advantages that overcome these defenses, permitting cell survival, proliferation, and metastasis. Countless happenstances can result in tr

FAQs

What biological functions does miR-181a regulate in cancer?

miR-181a regulates post-transcriptional control of transcripts involved in cell proliferation, cancer stemness, apoptosis, and immune responses.

How is miR-181a processed and matured according to the article?

Pri-miRNA is generated in the nucleus and processed by DROSHA/DGCR8 into pre-miRNA, which is exported to the cytoplasm; DICER and TRBP then produce the mature miRNA duplex.

Why is miR-181a considered a clinically relevant target for therapy?

It is described as a pan-cancer biomarker with therapeutic potential because it controls tumorigenic signaling pathways and immune responses, though success depends on developing specific therapeutics platforms.

Sep 21, 2026

Uploaded by Ophelia